ScreenerHero

PTGX Protagonist Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · protagonist-inc.com
140.92USD+1.61%Mkt Cap: 9.12B $P/E: 136.82

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric p…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap9.12B USD
Enterprise Value8.20B USD
Revenue (TTM)281.99M USD
Gross Profit281.99M USD
Net Income (TTM)-130.15M USD
Revenue/Share4.36 USD
Last Price140.92 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees141
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)136.82
P/E (Forward)-696.41
PEG—
EV/EBITDA136.95
EV/Revenue29.08
P/S31.82
P/B10.66
EPS (TTM)1.02
EPS (Forward)-0.20
52W Range
62.2480% of range160.81
52W High160.81 USD
52W Low62.24 USD
Profitability
Gross Margin100.00%
Oper. Margin74.37%
EBITDA Margin21.24%
Profit Margin-282.83%
ROE-21.17%
ROA-19.48%
Growth
Revenue Growth3749.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF57.67M USD
CapEx (TTM)1.59M USD
FCF Margin34.10%
FCF Yield1.05%
Net Debt-773.36M USD
Net Debt/EBITDA-12.91
Balance Sheet
Debt/Equity0.02
Current Ratio21.71
Quick Ratio21.58
Book Value/Sh13.01 USD
Cash/Share12.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)174.69 USD
Upside (mean)+24.0%
Target Range149.00 USD – 225.00 USD
149.00+24.0% to mean225.00
# Analysts13
Ownership
Shares Out.64.71M
Float52.89M
Insiders0.71%
Institutions119.66%
Short Interest
Short Ratio15.4d
Short % Float14.62%
Short % Out.12.58%
Shares Short8.14M
Short (prev mo.)7.79M
Technical
SMA 50145.07 (-2.9%)
SMA 200111.48 (+26.4%)
Beta1.52
S&P 52W Chg16.45%
Avg Vol (30d)667.16K
Avg Vol (10d)825.93K
Technical Indicators
RSI (14)47.3
MACD-1.2566
MACD Signal-0.8272
MACD Hist.-0.4293
BB Upper148.84 USD
BB Middle142.55 USD
BB Lower136.27 USD
BB Width8.82%
ATR (14)5.249 USD
Vol Ratio (20d)1.27x